… Recent genetic analysis using next-generation sequencing (NGS) vastly improved the
understanding of molecular mechanism of hematological malignancies. Many molecular targeting …

… The CD40 signaling may play a role in the development of B-cell hematological malignancies;
therefore anti-CD40 MoAb is an attractive option for targeted therapy [110]. Dacetuzumab …

… of how the targeted therapeutic approach holds promise for other hematologic malignancies…
Continued research efforts are needed to determine the optimal role of targeted therapy and …

… target therapy is a recently rapid progress in the management of hematological malignancies…
the treatment protocol plan and different other targeted therapeutic highly effective agents, …

… therapeutic target for the treatment of BPDCN, while a possible in the treatment of AML and
other hematological malignancies will … for a targeted therapy option for patients with BPDCN. …

… targeted to attack a particular molecular target in a cancer. Thus, targeted therapies are those
where the presumed target is … to empirical treatments where the target may not be known …

… histone methylation, and acetylation in hematologic malignancies. In addition, this review …
on hematologic malignancies. Furthermore, the implication of epigenetic regulation in targeted …

… Following on from the successful establishment of combination chemotherapy in the
1980s and 1990s, the development of molecular targeted therapies at the beginning of the …

… and parenteral targeted drugs used to treat solid organ and hematological malignancies and
to … Unlike classic cytotoxic chemotherapy, targeted therapies exert their antitumor effect by …

… We also present the case for reclassifying amino acid–targeting therapies as targeted
therapies against LSCs, which require specific amino acid–metabolic pathways for survival. …